According to Zacks, “CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex’s immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates. “
Separately, Cantor Fitzgerald reissued an overweight rating on shares of Celldex Therapeutics in a report on Tuesday, March 1st. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, Celldex Therapeutics has a consensus rating of Buy and an average target price of $65.00.
Celldex Therapeutics (NASDAQ:CLDX – Get Rating) last posted its quarterly earnings results on Monday, February 28th. The biopharmaceutical company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.01). Celldex Therapeutics had a negative return on equity of 21.98% and a negative net margin of 1,516.04%. The business had revenue of $0.33 million for the quarter, compared to analyst estimates of $1.39 million. During the same period last year, the firm posted ($0.26) EPS. As a group, equities analysts anticipate that Celldex Therapeutics will post -1.84 earnings per share for the current year.
Hedge funds have recently modified their holdings of the stock. Denali Advisors LLC bought a new stake in Celldex Therapeutics during the 4th quarter worth $43,000. Macquarie Group Ltd. bought a new stake in Celldex Therapeutics during the 3rd quarter worth $51,000. Captrust Financial Advisors bought a new stake in Celldex Therapeutics during the 3rd quarter worth $88,000. Royal Bank of Canada bought a new stake in Celldex Therapeutics during the 2nd quarter worth $90,000. Finally, O Shaughnessy Asset Management LLC grew its position in Celldex Therapeutics by 3,904.6% during the 3rd quarter. O Shaughnessy Asset Management LLC now owns 2,603 shares of the biopharmaceutical company’s stock worth $141,000 after acquiring an additional 2,538 shares during the last quarter. Institutional investors and hedge funds own 98.61% of the company’s stock.
About Celldex Therapeutics (Get Rating)
Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation.
- Get a free copy of the StockNews.com research report on Celldex Therapeutics (CLDX)
- It’s Time For FuboTV to Stand Out in the Sea of Streaming
- 3M Stock is Worth a Look Because of the Company it Keeps
- Landstar Systems Stock Can Bottom Down Here
- 3 Attractive Mid Cap Swing Trades
- Institutional Support For Rockwell International Begins To Erode
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.